Inhibrx clinical trials
Webb14 apr. 2024 · In the final analysis of all cohorts in the phase 2 ROAR basket trial, dabrafenib plus trametinib exhibited tumor-agnostic clinical activity in patients with rare BRAFV800E-mutated cancers ... WebbWe’re a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and ... Get in touch with our team and learn more about Inhibrx. Reach out. Torrey Pines Science Park 11025 N Torrey Pines Rd #200 La Jolla, CA 92037 (858) 795-4220 Scientific Approach; Investors;
Inhibrx clinical trials
Did you know?
Webbför 2 dagar sedan · At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and … Webb13 dec. 2024 · This is a Phase 1/2, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or …
Webb21 jan. 2024 · September 9, 2024 updated by: Inhibrx, Inc. An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Webb11 nov. 2024 · SAN DIEGO, Nov. 11, 2024 /PRNewswire/ --InhibRx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma.This data will be presented to attendees of …
Webb5 jan. 2024 · Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of biologic therapeutic candidates. Inhibrx utilizes diverse methods of … Webb11 okt. 2024 · Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb …
Webb18 jan. 2024 · Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart …
WebbClinical Research Associate Inhibrx, Inc. Jun 2024 - Present8 months We’re a clinical-stage biotechnology company dedicated to helping people with life-threatening … dc festivals 2021WebbClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. ClinicalTrials.gov is a registry and results database of publicly and … ge factor connexionWebb15 aug. 2024 · In November 2024, Inhibrx provided updated results from its ongoing Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with conventional chondrosarcoma.... ge facilities new englandWebbInhibrx is a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. The Senior Clinical Research Associate (CRA) is responsible for the management and monitoring of clinical sites participating in Inhibrx-sponsored clinical trials. dcf exit interviewWebb1 juli 2024 · Inhibrx has concluded the dose-escalation portion of the first-in-human Phase I clinical trial of INBRX-105 plus Keytruda in patients with locally advanced or metastatic solid tumours. A new targeted 4-1BB agonist, INBRX-105 is a multi-specific therapeutic candidate based on the company’s single domain antibody (sdAb) platform. ge fabric care dryer model dbxr463eg1wwWebb4 jan. 2024 · Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan … dcf evaluationsWebbClinical Research Associate Inhibrx, Inc. Jun 2024 - Present8 months We’re a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through... dcf facts